The role of blood pressure control in the prevention of cardiorenal disease in patients with chronic kidney disease.

BP TARGETS The ACC/AHA guidelines recommend antihypertensive therapy for treatment of average BP >130/>80 mmHg to reduce the risk of cardiovascular events in patients with clinically evident CVD and for patients with 10-year atherosclerotic cardiovascular disease (ASCVD) risk >10%. Measuring BP outside the office setting with an ambulatory BP monitoring (ABPM) device captures the effects of normal daily activities on BP, provides information on the behavior of BP during sleep and provides a greater number of readings than can be obtained during the typical office encounter. Keywords: cardiovascular disease; chronic kidney disease; hypertension; optimal blood pressure EN cardiovascular disease chronic kidney disease hypertension optimal blood pressure 264 270 7 02/15/23 20230201 NES 230201 INTRODUCTION Optimal blood pressure (BP) control has been debated between two schools of thought: standard BP control to a goal of systolic BP (SBP) <140 mmHg and intensive BP control with a goal of <120 mmHg. Treatment of resistant hypertension, seen in patients who are not meeting BP targets on three classes of antihypertensive medications, including diabetic therapy, should be considered for mineralocorticoid receptor antagonist therapy. [Extracted from the article]